2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, VWD, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Neutropenia, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

2613 Clinical outcomes of extracorporeal membrane oxygenation in patients with antiphospholipid syndrome: An ELSO registry analysis

Cecily Allen, MD, Michael Plazak, PharmD2, Alison Grazioli, MD3, Sameer S Kadri, MD, MS4
1 National Institutes of Health, Bethesda, Maryland, United States
2 University of Maryland Medical Center, Baltimore, Maryland, United States
3 University of Maryland School of Medicine, Baltimore, Maryland, United States
4 National Institutes of Health, Bethesda, Maryland, United States

Antiphospholipid syndrome (APS) predisposes patients to thrombotic and hemorrhagic complications, which are also inherent to extracorporeal membrane oxygenation (ECMO). Per the Extracorporeal Life Support Organization (ELSO) registry, hemorrhagic rates are 33% and 23% and thrombotic rates are 20% and 25% for veno-arterial (VA) and veno-venous (VV) ECMO respectively (Nunez 2022, Chung 2021). No cohort study has described the outcomes in patients with APS who receive ECMO. We aimed to characterize run details, complications, and outcomes in APS patients requiring VA or VV ECMO support. Additionally, we wanted to identify if there were differences in patient characteristics, bleeding and thrombotic events (BTEs) between survivors and non-survivors.

A multicenter retrospective study was conducted using the Extracorporeal Life Support Organization (ELSO) registry. We included adult patients (≥18 years) supported with VA or VV ECMO between 2015–2025 with a diagnosis of antiphospholipid syndrome (APS). Given there is no access to serologic antibody testing over time, APS was defined using ICD-10 codes (D68.61, D68.62, D68.312). Bleeding events included both medical (location based) and surgical bleeding. Thrombotic events included hemolysis, circuit changes, and stroke. Patient characteristics and outcomes were compared between VA and VV ECMO using the Kruskal-Wallis test for continuous variables and chi-square or Fisher's exact test for categorical variables, and survivors were compared with non-survivors separately within each modality, with univariable and multivariable logistic regression used to identify independent predictors of in-hospital mortality; variables with univariable p<0.20 were entered into the multivariable model. Temporal trends in ECMO utilization, case mix, survival, and bleeding/thrombotic event incidence were assessed using Poisson and logistic regression with year as a continuous predictor.

We identified 132 patients: 85 on VA-ECMO and 47 on VV-ECMO. ECMO duration was significantly longer for VV compared to VA-ECMO (18 vs. 8 days, p<0.001). Median age for the VA patients was 43 and 44 for VV. Patients on VA-ECMO had higher rates of pre-cannulation thrombosis 48 (56%) vs VV 10 (21%) (p<0.001). There were higher rates of BTE in the VA vs VV groups at 32 (38%) vs 9 (19%) respectively (p=0.045). BTE occurred less frequently in survivors (19.1%) than in non-survivors (44.6%) (p=0.004). Survival to discharge was 69% for the overall cohort, 39 (50%) for VA and 29 (63%) for VV (p=0.221).

When looking specifically at VA survivors vs non-survivors, there was no difference in age, however, non-survivors had a significantly lower pH and lower mean arterial pressure (MAP). For VV ECMO, when evaluating survivors vs non-survivors, survivors were younger (41 vs 50, p=0.010), and no significant difference was observed in pH or MAP. For VA survivors vs non-survivors there was no significant difference in BTE, however for VV, survivors had lower rates of bleeding at 2 (6.9%) vs non-survivors 6 (35%) (p=0.040). On multivariable analysis, no factor was independently associated with in-hospital mortality in either modality, though lower pH trended toward significance in VA (aOR 0.01, 95% CI 0.00–2.90, p=0.129) and older age trended toward significance in VV (aOR 1.08, 95% CI 1.00–1.18, p=0.078).

When evaluating changes over the years, there was an increase in the number of cannulations, increasing 13.13% per year (95% CI 4.07–22.98, p=0.020). Though not statistically significant, there is a trend towards improved survival at OR 1.10 per year (95% CI 0.96–1.26). There was a decrease in thrombotic rates over the years, OR per sequential year 0.81 (0.66–0.99; p=0.044). There was a trend towards decreased, but not statistically significant, bleeding rates at OR 0.94 per year (0.82–1.09). In patients who were on VA ECMO, survivors were cannulated in more recent years than non-survivors (2024 vs 2021, p=0.012).

Patients with APS supported on ECMO demonstrated hemorrhagic and thrombotic complication rates comparable to the broader ECMO population. Additionally, rates of BTE are decreasing and survival is improving, despite the increasing number of cannulations, likely reflecting improved technology and patient care over time. These findings suggest that APS alone should not preclude ECMO candidacy, and that acceptable outcomes can be achieved regardless of support modality.

Cecily Allen, MD: No relevant conflicts of interest to declare.